Docoh
Loading...

BLU Bellus Health

News

From Benzinga Pro
The Daily Biotech Pulse: Acadia Jumps On Data, vTv Shelves Psoriasis Study, More Setbacks For Merck's HIV Program, Decision Day For Daré
7 Dec 21
Biotech, Earnings, News, Penny Stocks, Small Cap, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
RBC Capital Maintains Outperform on BELLUS Health, Raises Price Target to $11
7 Dec 21
News, Price Target, Analyst Ratings
RBC Capital analyst Gregory Renza maintains BELLUS Health (NASDAQ:BLU) with a Outperform and raises the price target from $9 to $11.
BELLUS Health Q3 EPS $(0.29) Down From $(0.09) YoY, Sales $4.00K Up From $3.00K YoY
10 Nov 21
Earnings, News
BELLUS Health (NASDAQ:BLU) reported quarterly losses of $(0.29) per share. This is a 222.22 percent decrease over losses of $(0.09) per share from the same period last year. The company reported $4.00 thousand in sales
RBC Capital Maintains Outperform on BELLUS Health, Raises Price Target to $9
18 Oct 21
News, Price Target, Analyst Ratings
RBC Capital analyst Gregory Renza maintains BELLUS Health (NASDAQ:BLU) with a Outperform and raises the price target from $8 to $9.
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep 21
Biotech, M&A, News, Penny Stocks, Small Cap, FDA, IPOs, Top Stories, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28)
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep 21
Biotech, News, Penny Stocks, Offerings, Small Cap, FDA, IPOs, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14)
46 Biggest Movers From Yesterday
15 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Communications Systems, Inc. (NASDAQ: JCS) jumped 39.4% to close at $9.41 on Tuesday as the company declared a special dividend of $3.50 per share.
Why BELLUS Health Is Trading Higher Today
14 Sep 21
News, Trading Ideas
BELLUS Health (NASDAQ:BLU) shares are trading higher. The company on Monday announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractor chronic cough. HC Wainwright on Tuesday raised its price target on the stock.
Mid-Afternoon Market Update: Dow Tumbles 300 Points; Communications Systems Shares Climb
14 Sep 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Toward the end of trading Tuesday, the Dow traded down 0.87% to 34,565.88 while the NASDAQ fell 0.46% to 15,035.39. The S&P also fell, dropping 0.60% to 4,441.76.
Mid-Day Market Update: FuelCell Energy Jumps After Q3 Results; RedHill Biopharma Shares Slide
14 Sep 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Midway through trading Tuesday, the Dow traded down 0.49% to 34,698.16 while the NASDAQ fell 0.05% to 15,098.38. The S&P also fell, dropping 0.24% to 4,458.05.
36 Stocks Moving In Tuesday's Mid-Day Session
14 Sep 21
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers FuelCell Energy, Inc. (NASDAQ: FCEL) shares jumped 26% to $7.08 after the company reported better-than-expected Q3 results.
Mid-Morning Market Update: Markets Mostly Lower; US Annual Inflation Rate Slows to 5.3% in August
14 Sep 21
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets
Following the market opening Tuesday, the Dow traded down 0.26% to 34,778.27 while the NASDAQ rose 0.01% to 15,106.84. The S&P also fell, dropping 0.20% to 4,459.89.
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep 21
Biotech, M&A, News, Penny Stocks, Small Cap, FDA, General
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13)
HC Wainwright & Co. Maintains Buy on BELLUS Health, Raises Price Target to $14
14 Sep 21
News, Price Target, Analyst Ratings
HC Wainwright & Co. analyst Andrew Fein maintains BELLUS Health (NASDAQ:BLU) with a Buy and raises the price target from $10 to $14.
72 Biggest Movers From Yesterday
14 Sep 21
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
What's Going On With BELLUS Health's Stock Today?
13 Sep 21
News, Penny Stocks, Small Cap
BELLUS Health Inc (NASDAQ: BLU) is trading higher Monday after the company announced interim analysis from the Phase 2b SOOTHE trial of BLU-5937 in refractory chronic cough. The stock is experiencing high volatility, trading as high as $4.78 and as low as $3.63 in today's session.
Benzinga Pro's Top 5 Stocks To Watch For Monday, Sept. 13, 2021: JKS, NEGG, DVAX, BLU, MDXG
13 Sep 21
Pre-Market Outlook
Today's 5 Stock Ideas: JinkoSolar Holding Co (JKS) - JinkoSolar reports Q2 earnings on Wednesday, September 15th. Newegg Commerce (NEGG) - Shares up ~2.50% premarket. The company provided 2H and
BELLUS Health Stock Shines After Refractory Chronic Cough Trial Data
13 Sep 21
Biotech, Long Ideas, News, Penny Stocks, Health Care, Small Cap, Movers, Trading Ideas, General

Press releases

From Benzinga Pro
BELLUS Health Reports Third Quarter 2021 Financial Results and Business Highlights
10 Nov 21
Press Releases
- Announced positive findings from the Phase 2b SOOTHE trial administrative interim analysis, with at least one dose of BLU-5937 meeting the threshold for a high probability of clinical efficacy - - Phase 2b SOOTHE and
BELLUS Health Convenes Virtual Analyst Event to Discuss the Chronic Cough Landscape and its Selective P2X3 Antagonist BLU-5937
1 Nov 21
Press Releases
- Live webcast to be held on November 15th at 12:00 p.m. EST – BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for
BELLUS Health Announces Completion of Patient Enrollment in SOOTHE Phase 2b Trial for Refractory Chronic Cough and BLUEPRINT Phase 2a Trial for Chronic Pruritus Associated with Atopic Dermatitis
23 Sep 21
Press Releases
Topline results from both studies are expected in December 2021 BELLUS Health Inc. (NASDAQ:BLU, TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for
Thinking about buying stock in BELLUS Health, Grupo Financiero Galicia, Itamar Med, Kratos Defense & Security, or Monopar Therapeutics?
13 Sep 21
Opinion, Press Releases
NEW YORK, Sept. 13, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BLU, GGAL, ITMR, KTOS, and MNPR.
BELLUS Health Announces Positive Interim Analysis from the Phase 2b SOOTHE Trial of BLU-5937 in Refractory Chronic Cough
13 Sep 21
Press Releases
Interim analysis met the threshold for a high probability of clinical efficacy Data from interim analysis support accelerated planning for the Phase 3 program SOOTHE Phase 2b trial is on track to deliver topline